Julie Strizki

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

Alexandra Trkola, Shawn E. Kuhmann, Julie Strizki et al. · Proceedings of the National Academy of Sciences · 2002 · 304 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +15

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection <i>in vitro</i> and <i>in vivo</i>

Julie Strizki, Serena Xu, Nicole Wagner et al. · Proceedings of the National Academy of Sciences · 2001 · 300 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons.

Ehud Lavi, Julie Strizki, Anthony M. Ulrich et al. · PubMed · 1997 · 238 citations

Life Sciences, Neurobiology, Neuroscience +10

Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

Julie Strizki, Cécile Tremblay, Serena Xu et al. · Antimicrobial Agents and Chemotherapy · 2005 · 214 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17